Here are five things to know: 1. Under the definitive agreement, Natus would purchase Integra's neurosurgery assets in a $47.5 million all cash transaction. The company plans to use cash on hand and from its credit facility. 2. This acquisition would come to fruition when Integra finalizes its Johnson & Johnson's Codman Neurosurgery acquisition. 3. The agreement states Natus would acquire Integra's Camino ICP monitoring product line. 4. Natus would also gain U.S. rights associated with Integra's fixed pressure shunts and Codman's DURAFORM dural graft implant, standard EVD catheters and CSF collection systems. 5. Final regulatory approvals are still pending for both the Codman Neurosurgery and Integra neurosurgery asset acquisitions. The companies anticipate closing the transactions in October.